D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.23 MYR
Market Cap: 1.2B MYR
Have any thoughts about
Duopharma Biotech Bhd?
Write Note

Duopharma Biotech Bhd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Duopharma Biotech Bhd
Cash Equivalents Peer Comparison

Comparables:
P
PLABS
A
AHEALTH
R
RHONEMA
Y
YSPSAH
K
KOTRA

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Cash Equivalents
myr221.2m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
42%
P
PeterLabs Holdings Bhd
KLSE:PLABS
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
Apex Healthcare Bhd
KLSE:AHEALTH
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Cash Equivalents
myr139.2m
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
9%
K
Kotra Industries Bhd
KLSE:KOTRA
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Duopharma Biotech Bhd's Cash Equivalents?
Cash Equivalents
221.2m MYR

Based on the financial report for Jun 30, 2024, Duopharma Biotech Bhd's Cash Equivalents amounts to 221.2m MYR.

What is Duopharma Biotech Bhd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
42%

Over the last year, the Cash Equivalents growth was 63%. The average annual Cash Equivalents growth rates for Duopharma Biotech Bhd have been 27% over the past three years , and 42% over the past ten years .

Back to Top